The Los Angeles Times’ “Booster Shots” blog features an interview with Otto Yang, a professor at the Geffen School of Medicine at UCLA, who speaks about drug-resistant tuberculosis (TB) and the implications of a highly drug-resistant strain found in India. Yang said, “Obviously [the drug-resistant TB] could be devastating if it spreads, because treatment options are so limited. So far it seems not to have been as contagious as other strains, possibly because the mutations required to make it drug-resistant also make it a little less virulent” (Brown, 1/18).
“As the Global Fund [to Fight AIDS, Tuberculosis and Malaria] turns 10 on January 26, 2012, Nigerian families should join in the celebration of this innovative initiative that has saved the lives of millions here in Nigeria and across the globe,” Bello Bissalla, project manager for private sector and government partnerships at Friends of the Global Fund Africa, writes in Nigeria’s BusinessDay. “Much of the Global Fund’s success could be attributed to its performance-based financing mechanism, which creates room for transparency in the purchase, distribution and administration of drugs for these three diseases,” Bissalla continues, noting the grant review process “ensures that grant recipients show verified evidence of performance before receiving the next tranche of funding, thus ensuring transparency and implementation of the grant according to the plan.”
Noting the release of the WHO Global Tuberculosis Report 2012 this week, this Lancet editorial says the results show “good and bad news.” The editorial says, “The number of tuberculosis cases and deaths continues to fall … and overall, the world is on track to achieve the global target of a 50 percent reduction by 2015.” However, “with an estimated 8.7 million new cases (of which 13 percent represent co-infections with HIV) and 1.4 million deaths from tuberculosis in 2011,” the “global burden of tuberculosis remains huge,” the editorial states. The report also shows “alarming levels of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis,” the editorial notes.
South Africa “recently unveiled” a “newly reformed” South African National AIDS Council (SANAC), “coinciding with the announcement that the country has achieved universal access to HIV treatment,” PlusNews reports. Responding to a 2010 review of the body, SANAC “will now hold a new, annual meeting comprised of representatives from the research community, labor unions and people living with HIV,” at which “participants will discuss major policy issues and review progress on the country’s current national plan to address the twin epidemics of HIV and tuberculosis,” according to the news service.
In this post in the Center for Global Development’s (CGD) “Global Health Policy” blog, Victoria Fan, a CGD research fellow, and Rachel Silverman, a research assistant for the global health team at the center, examine the future of UNITAID. “Perhaps due to its relative obscurity and late entry to a crowded global health field, UNITAID has proactively worked to differentiate itself through a focus on commodities, market shaping, novel funding sources, and innovation,” but, “as UNITAID celebrates its sixth birthday …, it stands at a potential crossroads,” they write. Fan and Silverman note that a five-year evaluation report on the future of UNITAID, commissioned by its Executive Board, is forthcoming, and they highlight a paper (.pdf) in which they “outline some contradictions and limitations of UNITAID’s current approach.” They write, “We hope that the imminent evaluation provides the impetus for UNITAID to turn inward and do something truly innovative: buck institutional inertia, change course as necessary, and reinvent itself as the solution to 2012’s biggest global health challenges” (9/17).
The board of the Global Fund to Fight AIDS, Tuberculosis and Malaria began a two-day meeting in Geneva on Thursday, “with one topic high on the agenda: a new funding model,” Devex’s “Development Newswire” reports. “The board will tackle aspects of a new funding model, which, according to Global Fund Director of Communications Seth Faison, ‘will change the way the Global Fund has made grants for 10 years,’” the news service writes, adding that the model, according to the International HIV/AIDS Alliance, “will see the Global Fund dropping its ’round’ grant-making process and replacing it with a ‘more flexible’ system.” In addition, “an ‘iterative dialogue process’ is also reportedly being explored,” Devex reports. “The proposed reforms seem good for the fund and its beneficiaries … [b]ut some have expressed their concerns on the funding model under consideration, specifically on the ‘historical disease application’ approach,” the news service writes (Ravelo, 9/13). According to an article on the Stop TB Partnership website, the new approach “would cap the proportion of funding available to tuberculosis (TB) projects at 16 percent,” and the proposal, “which is based on the proportion of grants awarded to TB in the past, met with strong objections from the community of people working on TB worldwide” (9/13).
Small, Ingestible Sensor Can Track Patient Medication Intake, Activity Levels; Technology To Be Tested For TB Treatment
The FDA last month approved for use a small ingestible sensor that, when embedded into a pill, can help “keep track of whether a patient is taking their medicine on time,” Reuters reports. “The digital feedback technology, devised by Redwood City, California-based Proteus Digital Health Inc., can also prompt patients to take their medicine and even ask them to take a walk if they have been inactive for too long,” the news service writes. “Proteus has a partnership with the Bill & Melinda Gates Foundation and China’s Center for Disease Control and Prevention to test the technology in tuberculosis treatment,” Reuters notes, adding, “Pills for anything from the common cold to diabetes or cancer can be embedded.”
The Center for Global Health Policy’s “Science Speaks” blog reports the findings from the second edition of the 2011 Report on Tuberculosis (TB) Research Funding and Trends from 2005-2010, released Thursday by Treatment Action Group (TAG) and the Stop TB Partnership. “TB research and development investment increased 76 percent between 2005 and 2010, but investment has slowed markedly, with only two percent growth since 2009,” the blog notes, adding, “The $630.4 million 2010 investment is only one-third of the $2 billion needed to stay on track with the Global Plan to Stop TB 10-year implementation and research strategy to eliminate TB as a public health threat by 2050” (Mazzotta, 3/28).
NGOs Release Joint Statement Calling For Governments To Increase Payments To Global Fund To Fill Gap In TB Funding
Ahead of World Tuberculosis (TB) Day on March 24, three non-governmental organizations (NGOs) released a joint statement warning that “[a] $1.7 billion funding shortfall to fight [TB] over the next five years means 3.4 million patients will go untreated and gains made against the disease will be reversed,” Reuters reports. The International HIV/AIDS Alliance, the Stop AIDS Campaign and Results UK said in the statement that the cancellation of Round 11 grants from the Global Fund to Fight AIDS, Tuberculosis and Malaria was endangering the expansion of treatment and prevention programs, the news agency notes. The statement “called on governments to scale up funding of TB, HIV and malaria programs at a G20 meeting in Mexico in June in an effort to replenish the Global Fund with $2 billion,” according to Reuters (Mollins, 3/23).
Several blog posts recently commented on the upcoming World Tuberculosis (TB) Day, commemorated on March 24. “Despite a clear legislative mandate, the U.S. Global Health Initiative (GHI) has consistently failed to live up to the goals of” the Tom Lantos and Henry J. Hyde United States Leadership Against HIV/AIDS, Tuberculosis (TB), and Malaria Reauthorization Act, a landmark legislation passed by Congress in 2008, John Fawcett, legislative director for RESULTS, writes in the Center for Global Health Policy’s “Science Speaks” blog. He continues, “Current GHI TB treatment goals are less than 60 percent of what was mandated in the Lantos-Hyde Act,” and concludes, “As the final authorized fiscal year of the Lantos-Hyde Act is debated, there’s still time to embrace its mandate: a bold effort to confront the worldâ€™s leading curable infectious killer” (Mazzotta, 3/22). “As people across the globe celebrate World TB Day this week, several groups are highlighting the fact that the current tools to prevent, test, and treat tuberculosis (TB) are greatly outdated,” Ashley Bennett, senior policy associate at the Global Health Technologies Coalition (GHTC), writes in the GHTC “Breakthroughs” blog. She commends GHTC members for their efforts to develop new technologies (3/22).